Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $217.99M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.57M
Average 0.49M
BCYC Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Bicycle Therapeutics plcNASDAQ: BCYC
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit turns positive
Q1 FY2026 gross profit was $887K, compared with -$47.29M a year earlier. Trailing-twelve-month gross profit was -$7.53M. Over 3 fiscal years it compounded at +71.2% a year.
Context
- Gross profit amounted to 100.0% of revenue in FY2025, down 290.3 pp from a year earlier.
- Gross profit increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly gross profit holds near $887K or moves back toward the trailing-twelve-month quarterly average of -$1.88M.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 72.59M USD
- Year-over-year change
- +152.7%
- 4-year CAGR
- +57.8%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 72.59M | +152.7% |
| FY2024 | 2024-12-31 | (137.69M) | -6.3% |
| FY2023 | 2023-12-31 | (129.52M) | -995.5% |
| FY2022 | 2022-12-31 | 14.46M | +23.6% |
| FY2021 | 2021-12-31 | 11.7M | — |
Gross Profit vs competitors
How BCYC compares with its peers on the latest reported figures
- BCYC's LTM Mar 2026 gross profit of -$7.53M is the 9th highest of the 10 companies compared; the peer median is -$338K.
- Its year-over-year change of +94.3% is the 2nd highest of 8, against a peer median of -80.3%.
- Gross profit amounts to 11.9% of revenue for BCYC, versus a peer median of 68.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $106.66M | — | — | 92.0% | |
| LTM Mar 2026 | $71.82M | +2.1% | -29.1% | 90.7% | |
| LTM Mar 2026 | $69M | +1276.4% | — | 99.1% | |
| LTM Mar 2026 | $27.14M | -80.3% | -51.9% | 46.8% | |
| LTM Mar 2026 | -$338K | -101.0% | — | — | |
| LTM Mar 2026 | -$738K | -186.8% | — | — | |
| LTM Mar 2026 | -$1.23M | -307.3% | — | 12.4% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$5.01M | — | — | — |
| LTM Mar 2026 | -$7.53M | +94.3% | +71.2% | 11.9% | |
| LTM Mar 2026 | -$10.98M | +90.3% | — | 12.4% | |
| Peer median (excluding BCYC) | -$338K | -80.3% | -40.5% | 68.8% | |
Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 11.7M | 14.46M | 26.98M | 35.28M | 72.59M |
| Cost of Revenue | 0 | 0 | 156.5M | 172.97M | 0 |
| Gross Profit | 11.7M | 14.46M | (129.52M) | (137.69M) | 72.59M |
| Gross Margin | 100.0% | 100.0% | -480.1% | -390.3% | 100.0% |
| Research & Development | 44.88M | 81.61M | 156.5M | 172.97M | 240.28M |
| Selling, General & Admin | 32.44M | 49.51M | 59.83M | 71.46M | 80.02M |
| Operating Expenses | 77.32M | 131.12M | 60.43M | 72.18M | 320.3M |
| Depreciation & Amortization | 1.41M | 3.69M | 6.55M | 7.18M | 6.42M |
| EBITDA | (64.09M) | (107.21M) | (169.4M) | (164.89M) | (212.18M) |
| EBITDA Margin | -547.9% | -741.3% | -628.0% | -467.4% | -292.3% |
| Operating Income | (65.62M) | (116.65M) | (189.95M) | (209.87M) | (247.72M) |
| Operating Margin | -561.0% | -806.6% | -704.1% | -595.0% | -341.3% |
| Interest Income | 120K | 5.76M | 14M | 34.28M | 28.46M |
| Interest Expense | 2.98M | 3.34M | 3.26M | 1.73M | 206K |
| Other Income / Expenses | (2.86M) | 2.41M | 10.74M | 36.08M | 28.91M |
| Income Before Tax | (68.48M) | (114.24M) | (179.21M) | (173.8M) | (218.81M) |
| Pre-Tax Margin | -585.5% | -789.9% | -664.3% | -492.7% | -301.4% |
| Income Tax Expense | (1.66M) | (1.52M) | 1.46M | (4.77M) | 152K |
| Net Income | (66.82M) | (112.72M) | (180.66M) | (169.03M) | (218.96M) |
| Net Margin | -571.2% | -779.3% | -669.7% | -479.2% | -301.7% |
| EPS (Basic) | (2.67) | (3.80) | (5.08) | (2.91) | (3.16) |
| EPS (Diluted) | (2.67) | (3.80) | (5.08) | (2.90) | (3.16) |
| Weighted Avg Shares | 25.06M | 29.66M | 35.59M | 58.21M | 69.28M |
| Weighted Avg Shares (Diluted) | 25.06M | 29.66M | 35.59M | 58.21M | 69.28M |
Bicycle Therapeutics plc
NASDAQ:BCYC
Intrinsic Alpha fair value
Locked
Current Price
$3.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.